Cargando…
Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
BACKGROUND AND OBJECTIVES: Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal met...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519040/ https://www.ncbi.nlm.nih.gov/pubmed/28727768 http://dx.doi.org/10.1371/journal.pone.0180350 |
_version_ | 1783251573019770880 |
---|---|
author | Rosenzweig, Barak Rubinstein, Nimrod D. Reznik, Ed Shingarev, Roman Juluru, Krishna Akin, Oguz Hsieh, James J. Jaimes, Edgar A. Russo, Paul Susztak, Katalin Coleman, Jonathan A. Hakimi, A. Ari |
author_facet | Rosenzweig, Barak Rubinstein, Nimrod D. Reznik, Ed Shingarev, Roman Juluru, Krishna Akin, Oguz Hsieh, James J. Jaimes, Edgar A. Russo, Paul Susztak, Katalin Coleman, Jonathan A. Hakimi, A. Ari |
author_sort | Rosenzweig, Barak |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal metabolite abundances significantly associate with CRG, suggesting a causative relationship. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Tissue metabolomics data from 49 patients, with a median age of 60 years, were previously collected and the pre-operative fold-change of their contra to ipsi-lateral benign kidney volume served as a surrogate for their CRG. Contra-lateral kidney volume fold-change within a 3.3 +/- 2.1 years follow-up interval was used as a surrogate for long-term CRG. Using a multivariable statistical model, we identified metabolites whose abundances significantly associate with CRG. RESULTS: Our analysis found 13 metabolites in the benign (e.g. L-urobilin, Variable Influence in Projection, VIP, score = 3.02, adjusted p = 0.017) and 163 metabolites in the malignant (e.g. 3-indoxyl-sulfate, VIP score = 1.3, adjusted p = 0.044) tissues that significantly associate with CRG. Benign/tumor fold change in metabolite abundances revealed three additional metabolites with that significantly positively associate with CRG (e.g. p-cresol sulfate, VIP score = 2.945, adjusted p = 0.033). At the pathway level, we show that fatty-acid oxidation is highly enriched with metabolites whose benign tissue abundances strongly positively associate with CRG, both pre-operatively and long term, whereas in the tumor tissue significant enrichment of dipeptides and benzoate (positive association), glycolysis/gluconeogenesis, lysolipid and nucleotide sugar pentose (negative associations) sub-pathways, were observed. CONCLUSION: These data suggest that specific biological processes in the benign as well as in the tumor parenchyma strongly influence compensatory renal growth. |
format | Online Article Text |
id | pubmed-5519040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55190402017-08-07 Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients Rosenzweig, Barak Rubinstein, Nimrod D. Reznik, Ed Shingarev, Roman Juluru, Krishna Akin, Oguz Hsieh, James J. Jaimes, Edgar A. Russo, Paul Susztak, Katalin Coleman, Jonathan A. Hakimi, A. Ari PLoS One Research Article BACKGROUND AND OBJECTIVES: Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal metabolite abundances significantly associate with CRG, suggesting a causative relationship. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Tissue metabolomics data from 49 patients, with a median age of 60 years, were previously collected and the pre-operative fold-change of their contra to ipsi-lateral benign kidney volume served as a surrogate for their CRG. Contra-lateral kidney volume fold-change within a 3.3 +/- 2.1 years follow-up interval was used as a surrogate for long-term CRG. Using a multivariable statistical model, we identified metabolites whose abundances significantly associate with CRG. RESULTS: Our analysis found 13 metabolites in the benign (e.g. L-urobilin, Variable Influence in Projection, VIP, score = 3.02, adjusted p = 0.017) and 163 metabolites in the malignant (e.g. 3-indoxyl-sulfate, VIP score = 1.3, adjusted p = 0.044) tissues that significantly associate with CRG. Benign/tumor fold change in metabolite abundances revealed three additional metabolites with that significantly positively associate with CRG (e.g. p-cresol sulfate, VIP score = 2.945, adjusted p = 0.033). At the pathway level, we show that fatty-acid oxidation is highly enriched with metabolites whose benign tissue abundances strongly positively associate with CRG, both pre-operatively and long term, whereas in the tumor tissue significant enrichment of dipeptides and benzoate (positive association), glycolysis/gluconeogenesis, lysolipid and nucleotide sugar pentose (negative associations) sub-pathways, were observed. CONCLUSION: These data suggest that specific biological processes in the benign as well as in the tumor parenchyma strongly influence compensatory renal growth. Public Library of Science 2017-07-20 /pmc/articles/PMC5519040/ /pubmed/28727768 http://dx.doi.org/10.1371/journal.pone.0180350 Text en © 2017 Rosenzweig et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Rosenzweig, Barak Rubinstein, Nimrod D. Reznik, Ed Shingarev, Roman Juluru, Krishna Akin, Oguz Hsieh, James J. Jaimes, Edgar A. Russo, Paul Susztak, Katalin Coleman, Jonathan A. Hakimi, A. Ari Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
title | Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
title_full | Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
title_fullStr | Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
title_full_unstemmed | Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
title_short | Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
title_sort | benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519040/ https://www.ncbi.nlm.nih.gov/pubmed/28727768 http://dx.doi.org/10.1371/journal.pone.0180350 |
work_keys_str_mv | AT rosenzweigbarak benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT rubinsteinnimrodd benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT rezniked benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT shingarevroman benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT julurukrishna benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT akinoguz benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT hsiehjamesj benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT jaimesedgara benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT russopaul benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT susztakkatalin benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT colemanjonathana benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients AT hakimiaari benignandtumorparenchymametabolomicprofilesaffectcompensatoryrenalgrowthinrenalcellcarcinomasurgicalpatients |